When Pfizer reports 2012 results on Tuesday morning, we ought to get a sense of what Merck's year-end 2012 holds, by inference -- at least on industry trends.
I'll offer some analysis, as to what may be divined from the Pfizer tea leaves, for Merck, by Tuesday evening.
Keep it spinnin' in good karma, one and all!
No comments:
Post a Comment